“Swim Across America’s mission is to help advance cancer research,” said Rob Butcher, CEO of Swim Across America. “We are honored that our organization supported some of the initial research conducted by Dr. Diaz and team, which has now contributed to the approval of KEYTRUDA for this new indication.”
Stefanie Joho joined SAA – Baltimore this year to share her uplifting story. Four years ago at 22-years old she was diagnosed with stage 2 colon cancer. Stefanie went through repeated chemo with no positive response, and the cancer spread to stage 4. Her doctors gave her weeks to live. Desperate and not willing to give up, her sister googles and finds Dr. Luis Diaz at our beneficiary Johns Hopkins Medicine.
Dr. Diaz told Joho to come immediately to JHU where she participates in an immunotherapy clinical trial of Keytruda funded–yes funded–by your donations to Swim Across America. The trial saved her life (she has “no evidence of disease NED”), she has a bright future and Keytruda is now FDA approved. Read Stefanie’s story in the New York Times and if you are inspired by the work being done through Swim Across America labs, please consider donating to SAA: http://bit.ly/SAAdonation.
Genetic tests for mismatch repair deficiency are commercially available. But insurers might not pay for the drugs — Keytruda and Opdivo cost $150,000 a year — based on such a small study. The study was paid for by Swim Across America and other charities, and the National Institutes of Health. – New York Times